No GLP-1 weight-loss drug is approved for cats — not semaglutide, not tirzepatide, and not the feline implant that made headlines. What exists is three research programmes and one published weight trial. In that trial, 12 obese client-owned cats received exenatide twice daily for 12 weeks and lost a median 5.1% of body weight, against 3.2% on placebo — a difference that did not reach significance (P = 0.10). Set that beside the prevalence figure: 61% of US cats are overweight or obese (APOP, 2022). The gap between those two numbers is the whole story.
Why a cat is not a small person
Native GLP-1 has a plasma half-life of 1–2 minutes, chewed up by DPP-4; exenatide survives 3–4 hours in people. Cats clear it faster than that, which is why the implant programme exists at all: a short-acting peptide given by injection produces peaks and troughs, and cats are uncooperative about repeated injections. The OKV-119 researchers proposed a target plasma range of 1–4 ng/mL — a figure extrapolated from prototype release data, not a validated therapeutic window. No cat dose has been fixed by a controlled efficacy trial.
What the one published weight trial found
The 2016 placebo-controlled study is still the only randomised feline weight data for this drug class. Twelve obese but otherwise healthy client-owned cats received exenatide 1.0 µg/kg twice daily, or saline, for 12 weeks, on unchanged feeding. Median loss was 5.1% (range 1.7–8.4%) versus 3.2% (range −5.3 to 5.7%). Insulin concentration, plasma glucose and intravenous glucose tolerance were all unchanged (P > 0.05). Body composition by DXA and adipokine levels were unchanged too. Two cats had mild, self-limiting gastrointestinal signs and one had mild hypoglycaemia. The placebo group also lost weight — a reminder of what weekly weighing and a food diary do on their own.
The six-month implant: OKV-119 and MEOW-1
OKV-119 is a 2 mm × 21.5 mm titanium reservoir with a nanoporous titania membrane, releasing exenatide at 50–100 µg per day in prototype form. Insertion and removal under short anaesthesia each took 1–2 minutes, and plasma levels stayed measurable to day 35 in a 15-cat release study. Four healthy cats given a deliberately supratherapeutic configuration peaked at 9.3 ng/mL, held above 2 ng/mL for 28 days, and lost over 10% of body weight in week one and over 15% by week three — then regained it once the drug was spent. That is far faster than any safe feline rate, and it is why the tunable slow-release design matters: the implant can also be pulled if a cat stops eating. MEOW-1 began dosing in December 2025 under an FDA-CVM investigational application, with a three-month primary period and an optional three-month extension. No efficacy results had been published as of November 2026; the company's stated aim is a filing in 2027–2028.
The weekly shot: AKS-562c and HDM7006
Akston's candidate is an Fc-fusion GLP-1 protein built for once-weekly dosing. In 16 healthy young male cats, twelve weekly subcutaneous injections at 0.1–0.4 mg/kg produced no treatment-related toxicity and no treatment-emergent anti-drug antibodies; food intake fell and weight gain was limited. A Cornell client-owned study opened in November 2025, targeting 70 cats with an option to expand to 140, over roughly three months. Separately, the Chinese GLP-1/GIP dual agonist HDM7006 published pharmacokinetics in 48 healthy cats in October 2026: intravenous half-life 43.7 hours, subcutaneous half-life 39.8–47.1 hours, bioavailability 42.23–78.38%, and steady state after five weekly doses with no accumulation. It reported no weight endpoint at all.
Three programmes, side by side
| Programme | Route and interval | Stage, November 2026 | Published cat data |
|---|---|---|---|
| OKV-119 (Okava / Vivani) | Subcutaneous implant, up to 6 months | MEOW-1 trial, dosing since December 2025 | 4 cats for safety, 15 for release to day 35 |
| AKS-562c (Akston) | Subcutaneous injection, weekly | Cornell trial, 70 cats, expandable to 140 | 16 cats, 12 weeks, no toxicity or antibodies |
| HDM7006 (Huadong) | Subcutaneous injection, weekly | Pharmacokinetics published October 2026 | 48 cats, half-life 39.8–47.1 hours |
| Exenatide twice daily | Injection every 12 hours | Research only, not marketed for cats | 12 cats, 12 weeks, 5.1% versus 3.2% |
Every row is investigational. None of these products can be prescribed today, and none has an approved feline dose.
What 5% means on an actual cat
On a 6 kg cat, 5.1% is 306 g. The veterinary benchmark for safe loss is 0.5–2% of body weight per week, which on that cat is 30–120 g a week. A 3 kg surplus therefore takes 24 to 6 months to clear at the guideline rate — not the three weeks the early implant data produced. A common starting allowance is about 39 kcal per kg of target weight: a cat whose target is 5 kg starts near 195 kcal a day, then gets adjusted against the scale. Weigh weekly on the same scale, and treat a 5% drop in 30 days as the ceiling rather than the target.
Risks that weigh more heavily in cats
- Hepatic lipidosis. A cat that stops eating mobilises fat to the liver faster than it can export it. The four-cat implant study saw no liver signs, but four cats cannot rule out a risk that appears at scale.
- Muscle before fat. Fast loss on any plan costs lean mass; read fat cat, thin muscles for the muscle-condition score.
- Gut signs. The ASPCA's March 2026 alert on household GLP-1 exposures lists vomiting, diarrhoea, lethargy and reduced appetite as the common signs, with hypoglycaemia and pancreatitis possible.
- Device-specific issues. Feline injection-site sarcoma has not been excluded for a depot that sits under the skin for six months; the developers say so themselves.
- Human pens. Chewed pens, accidental injection of a human dose, and licking residue are the three routes the ASPCA documents. Over-the-counter "GLP-1-like" supplements add 5-HTP, xylitol and caffeine risks.
What to do this month instead
Score body condition on the 1–9 scale at home: ribs felt under a thin fat layer, a visible waist from above. Then start a log — the weekly weigh-in routine and the 12-week plan with four records are built around it. Cap treats at 10% of calories using the gram conversions. If the cat is diabetic, this class does not replace insulin; start with insulin storage and curves. Cost questions belong on the cost tool, not in a headline about a trial.
This article is for information only and does not replace veterinary diagnosis or a prescribed treatment plan. Obesity, diabetes and appetite change all need an examination, bloodwork and a diet chosen with a veterinarian.
Terms mentioned in this article
Frequently asked
Can I give my cat my own Ozempic pen?
No. No GLP-1 drug is approved for cats, and a human pen delivers a fixed dose that cannot be scaled to a 4 kg animal. The ASPCA lists vomiting, diarrhoea, lethargy and reduced appetite as the common signs after pet exposure, with hypoglycaemia and pancreatitis possible; chewed pens also risk sharp injury and obstruction. If an exposure happens, call your veterinarian or a poison service immediately.
How fast can a cat safely lose weight?
The veterinary benchmark is 0.5 to 2 percent of body weight per week — about 30 to 120 g on a 6 kg cat. Faster loss raises the risk of hepatic lipidosis and costs lean mass, so weekly weighing on the same scale matters more than any single number on a drug label.
Is the feline weight-loss implant available yet?
No. OKV-119 is available only inside the MEOW-1 trial, which began dosing in December 2025 and had published no efficacy results as of November 2026. The company has described a filing window of 2027 to 2028, which is a plan rather than an approval.
Related guides
- Feline Hypercalcemia: Total Ca Over 11 mg/dL
- Feline Panleukopenia: Signs, Lab Values, and Survival Odds
- Feline Thrombocytopenia: Platelets Under 50,000/µL
- Feline Triaditis: Pancreatitis, Cholangitis and IBD
- Fat Cat, Thin Muscles: 5-Point BCS, MCS and 1-2% a Week
- Feline Acne on the Chin: Grades, Chlorhexidine and Bowls